



United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FILING DATE FIRST NAMED INVENTOR		CONFIRMATION NO.	
10/081,599	02/20/2002	Cornelia Anna Mundt	GJE-87	9658	
23557	7590 12/16/2004		EXAMINER		
	CHIK LLOYD & SALIW	QIAN, CELINE X			
A PROFESS PO BOX 142	IONAL ASSOCIATION 2950	ART UNIT	PAPER NUMBER		
GAINESVII	LE, FL 32614-2950	1636			
			DATE MAILED: 12/16/2004		

Please find below and/or attached an Office communication concerning this application or proceeding.

		A	pplication No.		Applicant(s)			
		1	10/081,599		MUNDT ET AL.			
Of	fice Action Summary	E	xaminer		Art Unit			
			eline X Qian Pl		1636			
The I	MAILING DATE of this commu	nication appear	rs on the cove	r sheet with the co	orrespondence ad	Idress		
A SHORTEN THE MAILIN - Extensions of t after SIX (6) M - If the period for - If NO period for - Failure to reply Any reply recei	NED STATUTORY PERIOD F IG DATE OF THIS COMMUN ime may be available under the provision ONTHS from the mailing date of this com reply specified above is less than thirty (reply is specified above, the maximum s within the set or extended period for repl ived by the Office later than three months term adjustment. See 37 CFR 1.704(b).	IICATION. s of 37 CFR 1.136(a) munication. 30) days, a reply with tatutory period will ap y will, by statute, caus). In no event, howe hin the statutory mir pply and will expire use the application to	ever, may a reply be time nimum of thirty (30) days SIX (6) MONTHS from to become ABANDONED	ely filed will be considered timel he mailing date of this c (35 U.S.C. § 133).	ly. ommunication.		
Status								
1)⊠ Respo	nsive to communication(s) fil	ed on <u>24 Septe</u>	ember 2004.					
2a)⊠ This a	ction is FINAL .	2b) This act	tion is non-fin	al.				
	Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under <i>Ex parte Quayle</i> , 1935 C.D. 11, 453 O.G. 213.							
Disposition of (Claims							
4a) Of 5) ☐ Claim(6) ☑ Claim(7) ☐ Claim(
Application Pa	pers							
10)⊠ The dra Applica Replac	ecification is objected to by the awing(s) filed on 28 May 2005 ant may not request that any objected the drawing sheet(s) including the or declaration is objected the control of the con	2 is/are: a)⊠ a ection to the draw g the correction i	wing(s) be held is required if th	in abeyance. See e drawing(s) is obje	37 CFR 1.85(a). ected to. See 37 Cl			
Priority under 3	35 U.S.C. § 119							
12)⊠ Acknov a)⊠ All 1.⊠ 2.□ 3.□	wledgment is made of a claim b) Some * c) None of: Certified copies of the priority Certified copies of the priority Copies of the certified copies application from the Internation attached detailed Office action	or documents had documents had of the priority of the priority of the dureau (P	ave been rece ave been rece documents ha PCT Rule 17.2	vived. vived in Application ve been received (a)).	on No d in this National	Stage		
					•			
Attachment(s)	011 1 (277 207)		🗀		D=0 445			
	erences Cited (PTO-892) tsperson's Patent Drawing Review (I	PTO-948)		Interview Summary (Paper No(s)/Mail Dat				
3) Information Di	isclosure Statement(s) (PTO-1449 or fail Date		5) 🔲	Notice of Informal Pa		O-152)		

U.S. Patent and Trademark Office PTOL-326 (Rev. 1-04) Application/Control Number: 10/081,599

Art Unit: 1636

DETAILED ACTION

Claims 1-15 are pending in the application. Claims 5-14 are withdrawn from consideration for being directed to non-elected subject matter. Claims 1-4 and 15 are currently under examination.

This office action is in response to the Amendment filed on 9/24/04.

Response to Amendment

The rejection of claims 1-4 and 15 under 35 U.S.C. 112 2nd paragraph has been withdrawn in light of Applicant's amendment of the claims.

The rejection of claims 1-4 under 35 U.S.C 102 (b) has been withdrawn in light of Applicant's amendment of the claims.

The rejection of claims 1-4 and 15 under 35 U.S.C.112 1st paragraph is maintained for reasons set forth of the record mailed on 3/24/04 and further discussed below.

Response to Arguments

Claim Rejections - 35 USC § 112

The following is a quotation of the first paragraph of 35 U.S.C. 112:

The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same and shall set forth the best mode contemplated by the inventor of carrying out his invention.

Claims 1-4 and 15 are rejected under 35 U.S.C. 112, first paragraph, as failing to comply with the written description requirement. The claim(s) contains subject matter which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor(s), at the time the application was filed, had possession of the claimed invention.

Application/Control Number: 10/081,599

Art Unit: 1636

In response to this rejection, Applicants argue that the amended claims clarifies that the artificial chromosomes of the subject invention comprise a region that is not only between $C\delta$ and $C\gamma 3$, but also regulates immunoglobulin gene activation during lymphoid development. Applicants further assert that the specification discloses examples of such sequences as well as assay for readily identifying this activity. Applicants thus conclude that such teaching is sufficient for one skilled in the art to make and use the claimed invention without undue experimentation.

These arguments have been fully considered but deemed unpersuasive. As discussed in the previous office action, the written description requirement requires the specification to disclose a representative number of species by their complete structure or other identifying characteristics. Although the claims as amended recites a function for the claimed polynucleotide within the artificial chromosome, the specification has not describe the complete structure for the claimed genus of the artificial chromosome. As discussed in the previous office action, the specification only disclose a specific 1.3kb region between Cδ and Cγ3 of human IgH locus has enhancer function in early lymphoid development. The region between C δ and C γ 3 is 52kb. The claimed genus of a polynucleotide sequence between Cδ and Cγ3 of the human IgH locus encompasses a large number of nucleic acid sequences of various sizes that may or may not have the claimed function. Although the specification teaches assays for identifying such polynucleotides, it does not constitute the structural requirement for the statue. Whether one of the skilled in the art can make and use the claimed invention without undue experimentation is not relevant for satisfying the written description requirement of the claimed invention. A structural and functional relationship must be taught by the instant specification or prior art to

Application/Control Number: 10/081,599

Art Unit: 1636

satisfy the written description requirement. Since the specification fails to describe the claimed invention by their complete structure or identifying characteristics, the written description requirement is not met. Therefore, this rejection is maintained.

The claims will be allowable if amended to directed to the 1.3kb fragment.

Applicants indicate in the first page of the Remarks that claims 5-14 are cancelled (see 2nd paragraph). However, the claims set still indicates these claims as withdrawn. Applicants are reminded to clarify the status of the pending claims in the next response.

Conclusion

No claims are allowed.

THIS ACTION IS MADE FINAL. Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Celine X Qian Ph.D. whose telephone number is 571-272-0777. The examiner can normally be reached on 9:30-6:00 M-F.

Art Unit: 1636

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Remy Yucel Ph.D. can be reached on 571-272-0781. The fax phone number for the organization where this application or proceeding is assigned is 703-872-9306.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

Celine X Qian Ph.D.

Examiner

Art Unit 1636